Keros Therapeutics · 17 hours ago
Bioanalytical Co-Op
Lexington, Massachusetts, United States
Full-time
Onsite
New Grad
$28/hr - $32/hrKeros is focused on developing differentiated product candidates aimed at modulating TGF-β signaling for various disorders. The Bioanalytical Co-Op will support the establishment of pharmacokinetic, biomarker, and immunogenicity assays critical for clinical studies and will have the opportunity to contribute to the development of novel therapies.
BiotechnologyHealthcarePharmaceuticalHealth CareTherapeutics
Responsibilities
Support biomarker discovery and biomarker assays’ qualification efforts by reviewing relevant literature, selecting and evaluating the performance of various biomarker assays. Test study samples, analyze and interpret data to support translational or clinical studies
Maintain an organized work area and record experiments and data in electronic notebook
Analyze experimental data and present your work at team meetings and/or larger audiences
Participate in collaborative meetings with Contract Research Organization (CRO) partners
Qualification
Required
Previous experience with one of the following experimental assays: Protein detection methods, Biomarker assays, Immunogenicity assays
Minimum GPA of 3.0
Pursuing a degree in the life sciences, biotechnology, or a related field
Preferred
Experience in protein detection methods (MSD, ELISA etc.) preferred
Company
Keros Therapeutics
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Founded in 2015
51-200 employees
H1B Sponsorship
Keros Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (2)
2024 (2)
2023 (1)
2022 (3)
2021 (1)
Funding
Current Stage
Public CompanyTotal Funding
$379.5MKey Investors
Cowen Healthcare Investments,Foresite Capital,OrbiMed,VenrockPontifax
2024-01-03Post Ipo Equity· $140M
2020-11-13Post Ipo Equity· $149.5M
2020-04-07IPO
Leadership Team
Lorena Lerner
Chief Scientific Officer
Recent News
Keros Therapeutics, Inc.
2025-11-21
2025-11-20
Keros Therapeutics, Inc.
2025-11-19
Company data provided by crunchbase